Clinical Trial Update: An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL) [Phase 4]

View source ↗

Summary

Phase 4 expanded access program update for pegfilgrastim (Neulastim) in participants with non-Hodgkin's lymphoma, now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Neulastim (Pegfilgrastim)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Non-Hodgkin's Lymphoma | Phase 4 | Status: COMPLETED